GlyProVac secures 4.3 mDKK financing.

In Q4 2020 GlyProVac secured 4.3 mDKK in financing with Syddansk Innovation, Founders, Business Angel Niels Herman Kristiansen and Growth Fund Denmark. Raised capital will be used to test the efficacy of GlyProVac’s vaccine antigen in a large animal model. 

Visit our LinkedIN page for more news!

GlyProVac ApS is pursuing the development of glycoprotein based vaccines.

Antibiotics resistance (AMR) is one of the biggest health challenges of the 21st century, compromising our ability to treat even simple infections. In 2050, 10 million people are expected to die yearly from untreatable microbial infections. New solutions are urgently needed, and vaccines offer a safe alternative to antibiotics.

In GlyProVac ApS we aim to design and develop novel, efficient bacterial vaccine candidates based on our proprietary platform technology BEMAP. Using BEMAP, we have revealed that both benign as well as disease causing bacteria such as E. coli, Pseudomonas aeruginosa and Shigella, extensively modify their proteins with distinct sugar molecules, known as O-linked glycosylations. These modifications drastically influence the topology of the protein and are particularly well recognized by the human immune response.

Based on our paradigm changing discovery we believe inclusion of these modifications are crucial for the development of efficient bacterial vaccines. We are currently establishing PoC for this novel bacterial vaccine concept in the E. coli family (for diarrhoea and urinary tract infection).

Read more about BEMAP and our efforts on our TECHNOLOGY page.

Contact

Office Address:

GlyProVac ApS.

Rørhatten 4,

5220 Odense SØ.

Denmark

E-mail: boysen@GlyProVac.com